Steven Cohen’s Kymera Therapeutics KYMR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$23.6M Buy
+211,218
New +$24.2M 0.03% 817
2026
Q1
– Sell
-173,147
Closed -$13.5M – 4171
2025
Q4
$13.5M Sell
173,147
-753
-0.4% -$50.8K 0.02% 1159
2025
Q3
$9.8M Sell
173,900
-10,578
-6% -$477K 0.02% 805
2025
Q2
$8.05M Buy
+184,478
New +$6.35M 0.02% 820
2023
Q4
– Sell
-81,400
Closed -$1.13M – 2497
2023
Q3
$1.13M Buy
+81,400
New +$1.64M ﹤0.01% 1290
2022
Q2
– Sell
-652,800
Closed -$27.6M – 1520
2022
Q1
$27.6M Buy
652,800
+594,600
+1,022% +$25.1M 0.11% 246
2021
Q4
$3.7M Sell
58,200
-99,200
-63% -$5.78M 0.01% 732
2021
Q3
$9.25M Buy
157,400
+89,800
+133% +$5.21M 0.04% 508
2021
Q2
$3.28M Buy
+67,600
New +$2.93M 0.01% 678

Other funds holding KYMR

Steven Cohen's KYMR Position: Q3 2026 in Review

Steven Cohen opened a new position in Kymera Therapeutics (KYMR) in Q3 2026: 211,218 shares worth $23.6M. The stake represents 0.03% of the portfolio and ranks #817 among its holdings. This is a return to the name: Steven Cohen previously reported a position in KYMR as recently as Q4 2025.

Steven Cohen first reported a position in KYMR in Q2 2021 and has held it in 9 quarters since. The position peaked at $27.6M in Q1 2022. 298 funds tracked by Wall St. Rank hold KYMR as of Q3 2026.

  • Steven Cohen held 211,218 shares of Kymera Therapeutics worth $23.6M as of Q3 2026.
  • Kymera Therapeutics was a new Steven Cohen position in Q3 2026.
  • Kymera Therapeutics made up 0.03% of Steven Cohen's portfolio in Q3 2026, its #817 holding.
  • Steven Cohen first reported a position in Kymera Therapeutics in Q2 2021 and has held it in 9 quarters since.
  • Steven Cohen's Kymera Therapeutics position peaked at $27.6M in Q1 2022.
  • 298 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q3 2026.

Based on Point72 Asset Management's 13F filing for Q3 2026, filed 16 Nov 2026.